Fundraising momentum Gliknik has a history of multi-stage funding, including a recent 5.3M raise and prior rounds totaling significant capital, indicating an active investor interest and potential for strategic partnerships or grant-aligned collaborations to accelerate clinical development.

Clinical development focus Emphasis on autoimmune disease drugs and programs advancing toward clinical trials suggests opportunities for CRO partnerships, translational research services, and biomarker development collaborations to support trial readiness and regulatory submissions.

Early-stage scale Small team size (2-10 employees) combined with substantial fundraising implies reliance on external vendors and consultants; potential upsell of managed services, outsourcing, and platform tools for R&D operations and clinical data management.

Academic collaboration Past partnership with University of Maryland Baltimore County signals openness to academic alliances; explore opportunities in joint grant work, technology licensing, and access programs to advance organ transplant and immunology research.

Technology stack fit Current tech stack (iCIMS, WordPress, Shopify, Microsoft 365, analytics tools) indicates receptiveness to digital tooling, patient/research participant engagement platforms, CRM enhancements, and data governance solutions to streamline fundraising, partnerships, and communications.